Corcept Therapeutics | CORT - Net Income


Corcept Therapeutics reported $-31.76M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Acadia Pharmaceuticals USD 3.64M 269.93M Mar/2026
Alaunos Therapeutics USD -1.01M 153K Mar/2026
ANI Pharmaceuticals USD 29.49M 2.86M Mar/2026
Ardelyx USD -37.6M 37.2M Mar/2026
Aurora Cannabis CAD -71.1M 72.92M Mar/2026
BioMarin Pharmaceutical USD 105.53M 152.1M Mar/2026
Bristol-Myers Squibb USD 2.68B 1.59B Mar/2026
Canopy Growth CAD -157.11M 94.49M Mar/2026
Corcept Therapeutics USD -31.76M 56.05M Mar/2026
Eli Lilly USD 7.4B 760M Mar/2026
J&J USD 5.53B 299M Jun/2026
Knight Therapeutics CAD -3.79M 8.83M Sep/2025
Lexicon Pharmaceuticals USD -15.53M 2.76M Dec/2025
Merck USD -4.24B 7.2B Mar/2026
Nektar Therapeutics USD -36.08M 978K Dec/2025
Novartis USD 3.16B 747M Mar/2026
Novartis USD 3.16B 747M Mar/2026
Omeros USD -32.23M 23.81M Sep/2024
Pacira USD 2.92M 1.28M Mar/2026
Pfizer USD 2.69B 4.34B Mar/2026
Supernus Pharmaceuticals USD -2.29M 1.81M Mar/2026
TG Therapeutics USD 19.78M 3.26M Mar/2026